Multi-drug resistance due to efflux is one of the most pressing issues in treating bacterial infections. Antibiotics are extruded from the cell and cannot reach high enough intracellular concentrations to exert a therapeutic effect. While efforts to address this problem have focused on targeting one efflux pump at a time, resistance mutations can quickly develop. We propose to target TrmD to reduce efflux at multiple pumps simultaneously so as to accelerate bactericidal action. TrmD is a bacterial-specific S-adenosyl-methionine (AdoMet)-dependent tRNA methyl transferase that controls the accuracy of protein synthesis on the reading frame. Loss of TrmD leads to accumulation of +1 frameshift (+1FS) errors, which cause pre-mature termination of protein synthesis. We recently discovered that multiple efflux genes in E. coli and in other Gram (-) bacteria contain TrmD-dependent codons near the AUG start codon of the reading frame. We therefore hypothesize that targeting TrmD can inactivate protein expression of all of these genes. By reducing drug efflux of multiple pumps at once, we propose that targeting TrmD offers a novel solution to an unmet medical need. Successful targeting TrmD requires an understanding of its AdoMet domain and the quality control mechanism maintained by its product m1G37-tRNA. Using E. coli TrmD (EcTrmD) as a model, we provide these prerequisites in the following three aims.
In Aim 1, we will develop a molecular-level understanding of the AdoMet domain of TrmD. This domain has the unusual ability to maintain the methylation activity even at low levels of AdoMet. We will test the hypothesis that this ability is conferred by the unusual topological protein knot-fold of the domain that bends the methyl donor upon binding. Using both kinetic and cellular assays, we will determine how the protein knot-fold uses AdoMet binding to facilitate tRNA binding and to promote methyl transfer. We hypothesize that this facile coordination between AdoMet binding and catalytic activity is at the root of the unique biology of the domain.
In Aim 2, we will develo a mechanistic-level understanding of how the m1G37-tRNA product of TrmD improves the accuracy of protein synthesis on the ribosome. Accuracy will be determined by the ability of m1G37-tRNA to reduce +1FS errors at slippery mRNA sequences and to reduce decoding errors of cmo5U34, a wobble modification that frequently accompanies m1G37 in natural tRNAs.
In Aim 3, we will develop a cellular-level understanding of how inactivation of TrmD reduces synthesis of efflux proteins. We hypothesize that this reduction of efflux proteins will increase intracellular accumulation of traditional antibiotics, leading to faster bactericidal actin. We will also define the scope of TrmD activity using ribosome profiling to identify genes whose protein expression is arrested in TrmD deficiency. This will provide the basis for new strategies of antibiotic targeting and new paradigms for antibiotic discovery.

Public Health Relevance

Bacterial multi-drug resistance is one of the most pressing issues in modern medicine. We will determine how TrmD and its m1G37-tRNA product control synthesis of bacterial efflux pumps, thus providing the basis for targeting TrmD as a novel solution to reduce drug efflux. We will also determine how the unusual structure and function of the AdoMet domain of TrmD provide unique opportunities for novel drug discovery.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
1R01GM114343-01
Application #
8863358
Study Section
Prokaryotic Cell and Molecular Biology Study Section (PCMB)
Program Officer
Bender, Michael T
Project Start
2015-09-05
Project End
2019-04-30
Budget Start
2015-09-05
Budget End
2016-04-30
Support Year
1
Fiscal Year
2015
Total Cost
$312,168
Indirect Cost
$112,060
Name
Thomas Jefferson University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Masuda, Isao; Takase, Ryuichi; Matsubara, Ryuma et al. (2018) Selective terminal methylation of a tRNA wobble base. Nucleic Acids Res 46:e37
Oprescu, Stephanie N; Chepa-Lotrea, Xenia; Takase, Ryuichi et al. (2017) Compound heterozygosity for loss-of-function GARS variants results in a multisystem developmental syndrome that includes severe growth retardation. Hum Mutat 38:1412-1420
Po, Pengse; Delaney, Erin; Gamper, Howard et al. (2017) Effect of Nascent Peptide Steric Bulk on Elongation Kinetics in the Ribosome Exit Tunnel. J Mol Biol 429:1873-1888
Masuda, Isao; Igarashi, Takao; Sakaguchi, Reiko et al. (2017) A genetically encoded fluorescent tRNA is active in live-cell protein synthesis. Nucleic Acids Res 45:4081-4093
Fan, Haitian; Conn, Adam B; Williams, Preston B et al. (2017) Transcription-translation coupling: direct interactions of RNA polymerase with ribosomes and ribosomal subunits. Nucleic Acids Res 45:11043-11055
Hou, Ya-Ming; Matsubara, Ryuma; Takase, Ryuichi et al. (2017) TrmD: A Methyl Transferase for tRNA Methylation With m1G37. Enzymes 41:89-115
Gall, Aaron R; Datsenko, Kirill A; Figueroa-Bossi, Nara et al. (2016) Mg2+ regulates transcription of mgtA in Salmonella Typhimurium via translation of proline codons during synthesis of the MgtL peptide. Proc Natl Acad Sci U S A 113:15096-15101
Falk, Marni J; Gai, Xiaowu; Shigematsu, Megumi et al. (2016) A novel HSD17B10 mutation impairing the activities of the mitochondrial RNase P complex causes X-linked intractable epilepsy and neurodevelopmental regression. RNA Biol 13:477-85
Christian, Thomas; Sakaguchi, Reiko; Perlinska, Agata P et al. (2016) Methyl transfer by substrate signaling from a knotted protein fold. Nat Struct Mol Biol 23:941-948
Liu, Cuiping; Stonestrom, Aaron J; Christian, Thomas et al. (2016) Molecular Basis and Consequences of the Cytochrome c-tRNA Interaction. J Biol Chem 291:10426-36

Showing the most recent 10 out of 15 publications